CLINICAL TRIALS PROFILE FOR LINACLOTIDE

All Clinical Trials for linaclotide

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00402337 ↗	Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation	Completed	Ironwood Pharmaceuticals, Inc.	Phase 2	2006-11-01	The primary purpose of this study is to evaluate the efficacy and safety of administration of linaclotide acetate in patients with chronic constipation.
NCT00460811 ↗	Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)	Completed	Ironwood Pharmaceuticals, Inc.	Phase 2	2007-04-01	The purpose of this study is to determine the safety, efficacy, and dose response of a range of oral doses of linaclotide administered to patients meeting criteria for IBS-C.
NCT00730015 ↗	Trial of Linaclotide in Patients With Chronic Constipation	Completed	Forest Laboratories	Phase 3	2008-08-01	The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with chronic constipation (CC). The primary efficacy parameter is the percentage of patients in each dosing group that meet the protocol definition for Complete Spontaneous Bowel Movement (CSBM) Overall Responder.
NCT00730015 ↗	Trial of Linaclotide in Patients With Chronic Constipation	Completed	Ironwood Pharmaceuticals, Inc.	Phase 3	2008-08-01	The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with chronic constipation (CC). The primary efficacy parameter is the percentage of patients in each dosing group that meet the protocol definition for Complete Spontaneous Bowel Movement (CSBM) Overall Responder.
NCT00730171 ↗	An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation	Completed	Forest Laboratories	Phase 3	2008-09-01	The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C).
NCT00730171 ↗	An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation	Completed	Ironwood Pharmaceuticals, Inc.	Phase 3	2008-09-01	The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C).

Clinical Trial Conditions for linaclotide

Condition Name

Condition Name for linaclotide
Intervention	Trials
Chronic Constipation	10
Irritable Bowel Syndrome With Constipation	9
Chronic Idiopathic Constipation	4
Functional Constipation	4

Condition MeSH

Condition MeSH for linaclotide
Intervention	Trials
Constipation	35
Irritable Bowel Syndrome	19
Syndrome	17
Colorectal Neoplasms	2

Clinical Trial Locations for linaclotide

Trials by Country

Trials by Country for linaclotide
Location	Trials
United States	620
Canada	22
United Kingdom	13
China	8
Bulgaria	7

Trials by US State

Trials by US State for linaclotide
Location	Trials
Texas	23
Florida	23
Virginia	22
Pennsylvania	22
California	22

Clinical Trial Progress for linaclotide

Clinical Trial Phase

Clinical Trial Phase for linaclotide
Clinical Trial Phase	Trials
PHASE4	2
PHASE1	1
Phase 4	5

Clinical Trial Status

Clinical Trial Status for linaclotide
Clinical Trial Phase	Trials
Completed	28
Recruiting	6
Not yet recruiting	5

Clinical Trial Sponsors for linaclotide

Sponsor Name

Sponsor Name for linaclotide
Sponsor	Trials
Ironwood Pharmaceuticals, Inc.	23
Forest Laboratories	15
Astellas Pharma Inc	6

Sponsor Type

Sponsor Type for linaclotide
Sponsor	Trials
Industry	54
Other	42
NIH	2

Linaclotide: Clinical Trials Update and Market Outlook

Last updated: April 28, 2026

What is linaclotide and what indications drive demand?

Linaclotide is a first-in-class guanylate cyclase-C (GC-C) agonist used for chronic constipation syndromes and irritable bowel disease subsets. In commercial practice it is most often positioned as a targeted GI motility and fluid-secretion therapy with rapid symptom onset in constipation-related end points.

Approved uses (by region; not exhaustive):

• Chronic idiopathic constipation (CIC)
• IBS with constipation (IBS-C)
• IBS with constipation in adults (label language varies by agency)

Key practical implication for market sizing: linaclotide demand is driven by the addressable patient pools in CIC and IBS-C, plus physician adoption in settings where tolerability and onset align with formularies. Pricing and access dominate unit economics once penetration matures.

---

What is the current state of linaclotide clinical development?

Sufficient, up-to-date trial-by-trial results (with identifiers, endpoints, and timelines) are required to produce a complete, accurate clinical trials update. The information provided in the prompt is not enough to support that level of granularity, so a full trial update cannot be produced.

---

How does the competitive landscape shape linaclotide pricing power?

Linaclotide competes in a constipation-and-IBS-C therapeutic band dominated by:

• Other GC-C agonists (class competition for similar mechanism and endpoints)
• Alternative symptom control therapies used in chronic constipation and IBS-C (with different efficacy-tolerability profiles)

Market structure effect: When multiple therapies achieve guideline inclusion and payers build interchangeability by class, differentiation shifts to:

• time-to-response and symptom durability (constipation burden outcomes)
• tolerability and adherence (adverse-event profile and discontinuation rates)
• formulary placement and contracting (rebates, preferred status, step edits)

Actionable read-through for commercial strategy: late-stage and real-world adoption typically tracks formulary outcomes more than incremental trial claims once several options are established. For investors and R&D planners, the most decision-relevant variable is often access rather than mechanism.

---

What is the current market analysis for linaclotide?

A complete market analysis requires current data inputs such as:

• global and regional sales by year
• channel mix (hospital vs retail, if applicable)
• net price and payer coverage evolution
• competitor share changes and class growth rates

The prompt does not provide those inputs, and a complete and accurate market analysis cannot be produced under the required standard of hard data.

---

What is the market projection for linaclotide?

Market projection requires an auditable base year and forecast drivers (patient growth, penetration, price erosion, and competitive dynamics) with specific numbers. Those data are not present in the prompt, so a full quantitative projection cannot be produced.

---

Key decision points for R&D and investment (without speculative numbers)

Even without a numerical forecast, three deterministic drivers usually govern linaclotide’s forward value:

1. Payer access and net pricing trajectory

   • For mature GI brands, net price is the dominant driver of margin trajectory as contracts renew.

2. Class competitive pressure

   • When class alternatives expand, incremental switching becomes a margin issue and a volume issue.

3. Lifecycle management and evidence refresh

   • New endpoints, subgroup analyses, and real-world effectiveness can support persistence in formularies, but only if they map to payer decision criteria (response durability, discontinuation, and health-care utilization).

These three levers determine whether growth is achieved via net sales expansion, mix improvement, or both.

---

Key Takeaways

• Linaclotide demand is anchored in CIC and IBS-C, with patient pool size and payer coverage determining volume.
• A complete clinical trials update and market projection with hard numbers cannot be produced from the information provided.
• For decision-making, the most material forward drivers are net pricing and access, GC-C class competition, and evidence refresh that matches payer endpoints.

---

FAQs

1. Is linaclotide a GC-C agonist?
Yes. Linaclotide is a guanylate cyclase-C agonist used for constipation-related GI conditions.

2. Which indications drive linaclotide use?
Chronic idiopathic constipation and IBS with constipation are the principal commercial indications.

3. What typically determines linaclotide growth after initial adoption?
Formulary positioning, payer contracting, and net price dynamics usually outweigh incremental clinical differentiation once the class is established.

4. What are the main competitive threats?
Other therapies within constipation and IBS-C, including GC-C agonists with similar mechanism-adjacent positioning.

5. What evidence most influences payer decisions in this area?
Clinically meaningful response rates, durability, discontinuation/tolerability, and health-care utilization outcomes tied to response.

---

References

[1] No sources were provided in the prompt, and no external citations were generated in this response.